 |
Safety of Long-acting Beta-agonists in Asthma: A Review CME DisclosuresRelease Date: February 27, 2008; Valid for credit through February 27, 2009 |
| Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | |
| Contents of This CME Activity | |
| Legal Disclaimer | |
| The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Specify the characteristics of long-acting beta2-agonists (LABAs)
- Describe research into the anti-inflammatory effects, if any, of LABAs
- Identify appropriate clinical use of LABAs for the treatment
of asthma
- Describe genetic factors that can influence the safety of beta2-agonist medications
Authors and Disclosures John Oppenheimer, MD
Disclosure: John Oppenheimer, MD, has declared that he has conducted research for, received a grant from, and/or acted as a consultant for GlaxoSmithKline, A2,
Schering-Plough, Sepracor Inc., Novartis, and Merck. Harold S. Nelson, MD
Disclosure: Harold S. Nelson, MD, has declared that he has consultant arrangements with Genentech/Novartis, Curalogic, GlaxoSmithKline, Schering-Plough, Dey Laboratories, Dynavax Technologies, Abbott Laboratories, and MediciNova. Dr. Nelson has also disclosed that he has received grants/research support from the following: Schering-Plough, TEVA,
Clinical Therapeutics, Wyeth, ALTANA, Behringer, Novartis, AstraZeneca, Sepracor Inc., and Genentech. Dr. Nelson has also disclosed that he has served on the speaker's bureau for GlaxoSmithKline and AstraZeneca. Charles P. Vega, MD
Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
